<div id="readability-page-1"><p>ChromaDex Co. (NASDAQ:CDXC - Get Free Report) saw a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 2,070,000 shares,  an increase of 6.7% from the December 31st total of 1,940,000 shares. Based on an average trading volume of 1,270,000 shares, the short-interest ratio is presently 1.6 days. Approximately 4.3% of the shares of the company are short sold.</p><h2>ChromaDex Price Performance</h2><p>CDXC stock traded down $0.14 during trading hours on Monday, reaching $5.49. The stock had a trading volume of 342,099 shares, compared to its average volume of 347,043. ChromaDex has a fifty-two week low of $1.46 and a fifty-two week high of $7.97. The stock has a market capitalization of $419.33 million, a PE ratio of 549.55 and a beta of 2.21. The stock has a 50-day simple moving average of $6.07 and a 200 day simple moving average of $4.69. </p><p>ChromaDex (NASDAQ:CDXC - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The company reported $0.02 earnings per share (EPS) for the quarter. The business had revenue of $25.58 million during the quarter, compared to the consensus estimate of $23.70 million. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. During the same period in the previous year, the company posted ($0.01) EPS.  On average, sell-side analysts forecast that  ChromaDex will post 0.04 EPS for the current fiscal year. </p><h2>Wall Street Analysts Forecast Growth</h2><p>A number of research analysts have recently commented on the stock. StockNews.com lowered shares of ChromaDex from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research report on Wednesday, January 15th. Roth Mkm increased their price target on ChromaDex from $6.00 to $8.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, November 6th. Finally, HC Wainwright increased their price target on shares of ChromaDex from $6.00 to $8.00 and gave the company a &#34;buy&#34; rating in a research note on Monday, November 4th.</p><p><b>Read Our Latest Report on ChromaDex</b></p><h2>Insider Buying and Selling at ChromaDex</h2><p>In other news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the company's stock in a transaction on Friday, December 13th. The stock was sold at an average price of $6.19, for a total transaction of $230,026.59. Following the completion of the sale, the director now directly owns 244,179 shares of the company's stock, valued at $1,511,468.01. This represents a 13.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 9.64% of the stock is currently owned by insiders. </p><h2>Institutional Inflows and Outflows</h2><p>A number of institutional investors and hedge funds have recently made changes to their positions in CDXC. BSW Wealth Partners bought a new stake in shares of  ChromaDex during the 3rd quarter valued at about $324,000.  BNP Paribas Financial Markets raised its stake in shares of  ChromaDex by 1,885.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 73,272 shares of the company's stock valued at $267,000 after purchasing an additional 69,582 shares during the period.  State Street Corp lifted its holdings in shares of  ChromaDex by 11.3% in the third quarter. State Street Corp now owns 618,028 shares of the company's stock worth $2,256,000 after buying an additional 62,692 shares in the last quarter.  Barclays PLC grew its position in shares of  ChromaDex by 322.1% during the 3rd quarter. Barclays PLC now owns 70,072 shares of the company's stock valued at $256,000 after purchasing an additional 53,472 shares in the last quarter.  Finally, Sargent Investment Group LLC purchased a new stake in shares of  ChromaDex in the 4th quarter valued at about $263,000. Institutional investors own  15.41% of the company's stock. </p><h2>ChromaDex Company Profile</h2> (Get Free Report)<p>ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than ChromaDex</li><li>How to Start Investing in Real Estate</li><li>How to Invest in Small Cap Stocks</li><li>Insider Trading - What You Need to Know</li><li>These Are the Dividend Stocks Insiders Bought in January</li><li>What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story</li><li>How the ‘No Buy’ Trend of 2025 Is Boosting These 3 Stocks</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in ChromaDex Right Now?</h2><p>Before you consider ChromaDex, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ChromaDex wasn't on the list.</p><p>While ChromaDex currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CDXC

NAGE

<p>ChromaDex Co. (NASDAQ:CDXC) experienced a 6.7% increase in short interest in January, totaling 2,070,000 shares as of January 15th. The days-to-cover ratio is 1.6 days, with approximately 4.3% of shares sold short. The stock traded down to $5.49, with a market cap of $419.33 million. Analysts have mixed ratings, with some raising price targets to $8.00. Insider trading activity includes a director selling 37,161 shares. Institutional ownership stands at 15.41%.</p>

ChromaDex Co. (NASDAQ:CDXC) Sees Large Increase in Short Interest